{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:52:33Z","timestamp":1764996753345,"version":"3.46.0"},"reference-count":41,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IRDR"],"published-print":{"date-parts":[[2025,11,30]]},"DOI":"10.5582\/irdr.2025.01025","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T22:09:17Z","timestamp":1758838157000},"page":"266-276","source":"Crossref","is-referenced-by-count":0,"title":["Characteristics of rare diseases cases: A summary analysis of hospitalized patients at a hospital in Western China from 2015 to 2023"],"prefix":"10.5582","volume":"14","author":[{"given":"Qi","family":"Wang","sequence":"first","affiliation":[{"name":"Medical Affairs Department, Gansu Provincial Hospital, Lanzhou, Gansu, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Ward 6, The Second Hospital of Lanzhou University, Lanzhou, Gansu, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[{"name":"Quality Control Department, Gansu Provincial Hospital, Lanzhou, Gansu, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"He","sequence":"additional","affiliation":[{"name":"Medical Affairs Department, Gansu Provincial Hospital, Lanzhou, Gansu, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Montserrat Moliner A, Walig\u00f3ra J. The European union policy in the field of rare diseases. Public Health Genomics. 2013; 16:268-277.","DOI":"10.1159\/000355930"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. The Lancet Diabetes Endocrinology. Spotlight on rare diseases. Lancet Diabetes Endocrinol. 2019; 7:75.","DOI":"10.1016\/S2213-8587(19)30006-3"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, Murphy D, Le Cam Y, Rath A. Estimating cumulative point prevalence of rare diseases: Analysis of the Orphanet database. Eur J Hum Genet. 2020; 28:165-173.","DOI":"10.1038\/s41431-019-0508-0"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Richter T, Nestler-Parr S, Babela R, Khan ZM, Tesoro T, Molsen E, Hughes DA; International Society for Pharmacoeconomics and Outcomes Research Rare Disease Special Interest Group. Rare disease terminology and definitions-a systematic global review: Report of the ISPOR rare disease special interest group. Value Health. 2015; 18:906-914.","DOI":"10.1016\/j.jval.2015.05.008"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Melnikova I. Rare diseases and orphan drugs. Nat Rev Drug Discov. 2012; 11:267-268.","DOI":"10.1038\/nrd3654"},{"key":"6","unstructured":"6. European Union. Regulation (EC) No 141\/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products (2000). <i>https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=celex%3A32000R0141<\/i> (accessed October 31, 2024)."},{"key":"7","unstructured":"7. U.S. Food &amp; Drug. Rare Diseases at FDA. <i>https:\/\/www.fda.gov\/patients\/rare-diseases-fda<\/i> (accessed October 31, 2024)."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Lu Y, Han J. The definition of rare disease in China and its prospects. Intractable Rare Dis Res. 2022; 11:29-30.","DOI":"10.5582\/irdr.2022.01034"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Groft SC, Posada M, Taruscio D. Progress, challenges and global approaches to rare diseases. Acta Paediatr. 2021; 110:2711-2716.","DOI":"10.1111\/apa.15974"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Vandeborne L, van Overbeeke E, Dooms M, De Beleyr B, Huys I. Information needs of physicians regarding the diagnosis of rare diseases: A questionnaire-based study in Belgium. Orphanet J Rare Dis. 2019; 14:99.","DOI":"10.1186\/s13023-019-1075-8"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Lane R. Shuyang Zhang: Pioneer in China&apos;s rare diseases programme. Lancet. 2019; 394:1134.","DOI":"10.1016\/S0140-6736(19)32168-3"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Lu Y, Gao Q, Ren X, Li J, Yang D, Zhang Z, Han J. Incidence and prevalence of 121 rare diseases in China: Current status and challenges: 2022 revision. Intractable Rare Dis Res. 2022; 11:96-104.","DOI":"10.5582\/irdr.2022.01093"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. He J, Song P, Kang Q, Zhang X, Hu J, Yang Y, Tang M, Chen D, Hu S, Jin C. Overview on social security system of rare diseases in China. Biosci Trends. 2019; 13:314-323.","DOI":"10.5582\/bst.2019.01209"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Peng A, Fan X, Zou L, Chen H, Xiang J. Trend of clinical trials of new drugs for rare diseases in China in recent 10 years. Orphanet J Rare Dis. 2023; 18:114.","DOI":"10.1186\/s13023-023-02713-6"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Cui Y, Zhou X, Han J. China launched a pilot project to improve its rare disease healthcare levels. Orphanet J Rare Dis. 2014; 9:14.","DOI":"10.1186\/1750-1172-9-14"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. He J, Kang Q, Hu J, Song P, Jin C. China has officially released its first national list of rare diseases. Intractable Rare Dis Res. 2018; 7:145-147.","DOI":"10.5582\/irdr.2018.01056"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Tang M, Yang Y, Ye Z, Song P, Jin C, Kang Q, He J. Release and impact of China&apos;s &quot;second list of rare diseases&quot;. Intractable Rare Dis Res. 2023; 12:251-256.","DOI":"10.5582\/irdr.2023.01086"},{"key":"18","unstructured":"18. Bureau of Medical Administration of the National Health Commission of the People&apos;s Republic of China. Notification on adjusting the members of the national rare disease diagnosis and treatment collaborative network hospitals and personnel in the Office. <i>https:\/\/www.nhc.gov.cn\/yzygj\/c100068\/202403\/e0328f505bcc47619e464148b2304dc0.shtml<\/i> (accessed October 31, 2024). (in Chinese)"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Feng S, Liu S, Zhu C, Gong M, Zhu Y, Zhang S. National rare diseases registry system of China and related cohort studies: Vision and roadmap. Hum Gene Ther. 2018; 29:128-135.","DOI":"10.1089\/hum.2017.215"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Gong L, He Q. Establishing a rare diseases center: Experiences from Western China. Intractable Rare Dis Res. 2021; 10:60-61.","DOI":"10.5582\/irdr.2020.03091"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Yang Y, Kang Q, Hu J, Kong F, Tang M, He J, Jin C. Accessibility of drugs for rare diseases in China: Policies and current situation. Intractable Rare Dis Res. 2019; 8:80-88.","DOI":"10.5582\/irdr.2019.01068"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Cai X, Yang H, Genchev GZ, Lu H, Yu G. Analysis of economic burden and its associated factors of twenty-three rare diseases in Shanghai. Orphanet J Rare Dis. 2019; 14:233.","DOI":"10.1186\/s13023-019-1168-4"},{"key":"23","unstructured":"23. Shuyang Z, Xue Z. Recent polices and practice in rare diseases in China. Journal of Rare Diseases. 2022; 1:1-6. (in Chinese)"},{"key":"24","unstructured":"24. Report of Rare Disease in China (2018). China medical science and technology press (Jie D, Lin W, eds.). Beijing, China. 2018; PP. 142-148. (in Chinese)"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Guo J, Liu P, Chen L, Lv H, Li J, Yu W, Xu K, Zhu Y, Wu Z, Tian Z, Jin Y, Yang R, Gu W, Zhang S; Administrative Group of National Rare Diseases Registry System of China. National Rare Diseases Registry System (NRDRS): China&apos;s first nation-wide rare diseases demographic analyses. Orphanet J Rare Dis. 2021; 16:515.","DOI":"10.1186\/s13023-021-02130-7"},{"key":"26","unstructured":"26. Bureau of Medical Administration of the National Health Commission of the People&apos;s Republic of China. Notification on launching the registration of rare disease case diagnosis and treatment information (2019). <i>https:\/\/www.nhc.gov.cn\/yzygj\/c100068\/201910\/1442aeb8bb5643939a83713f410bc206.shtml<\/i> (accessed October 28, 2024). (in Chinese)"},{"key":"27","unstructured":"27. Shi XM, Liu H, Wang L, Wang ZX, Dong CY, Wang YF, Yao C, Zhan SY, Ding J, Li Y. Study on the current situation of China&apos;s first list of rare diseases based on 15 million hospitalizations. Zhonghua Yi Xue Za Zhi. 2018; 98:3274-3278. (in Chinese)"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Shi X, Liu H, Zhan S, Wang Z, Wang L, Dong C, Wang Y, Yao C, Ding J, Li Y. Rare diseases in China: Analysis of 2014-2015 hospitalization summary reports for 281 rare diseases from 96 tertiary hospitals. Orphanet J Rare Dis. 2019; 14:160.","DOI":"10.1186\/s13023-019-1137-y"},{"key":"29","unstructured":"29. Qian L, Jianmin G, Yiping M. Analysis of the characteristics of inpatients with rare diseases in a hospital from 2015 to 2019. Chinese Health Quality Management, 2021; 28:27-30. (in Chinese)"},{"key":"30","unstructured":"30. Wen X, Wang SS, Cai J, Ren JP, Gu H. Characteristics of rare diseases in Zhejiang province, 2007-2017. Zhonghua Liu Xing Bing Xue Za Zhi. 2020; 41:400-405. (in Chinese)"},{"key":"31","unstructured":"31. Lingyan Z, Jie H, Cheng Y, Dajin L, Jinmei L, Jie S, RuiBa L, Huabin G. Analysis of inpatient cases of rare diseases in a tertiary first-class hospital in Yunnan Province from 2015 to 2019. Chinese Medical Record. 2022; 23:79-82. (in Chinese)"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Vandeborne L, van Overbeeke E, Dooms M, De Beleyr B, Huys I. Information needs of physicians regarding the diagnosis of rare diseases: A questionnaire-based study in Belgium. Orphanet J Rare Dis. 2019; 14:99.","DOI":"10.1186\/s13023-019-1075-8"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Stolk P, Willemen MJ, Leufkens HG. Rare essentials: Drugs for rare diseases as essential medicines. Bull World Health Organ. 2006; 84:745-751.","DOI":"10.2471\/BLT.06.031518"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Yang G, Cintina I, Pariser A, Oehrlein E, Sullivan J, Kennedy A. The national economic burden of rare disease in the United States in 2019. Orphanet J Rare Dis. 2022; 17:163.","DOI":"10.1186\/s13023-022-02299-5"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Aranda-Reneo I, Oliva-Moreno J, Pe\u00f1a-Longobardo LM, Villar-Hern\u00e1ndez \u00c1R, L\u00f3pez-Bastida J. Economic burden and health-related quality of life in patients with epidermolysis bullosa in Spain. Orphanet J Rare Dis. 2024; 19:352.","DOI":"10.1186\/s13023-024-03328-1"},{"key":"36","unstructured":"36. Wen Z, Yue M, Qian L, Zheng C, Wenjia L, Xiaoting Y. An analysis of influencing factors on hospitalization expenses of the top five rare diseases in a tertiary general hospital. Modern Hospitals, 2023; 23:585-588. (in Chinese)"},{"key":"37","unstructured":"37. Liu YQ, Liu X, Zuo W, Wang SH, Zhang B, Zhang SY. Study on drug list and accessibility of rare diseases based on the China&apos;s second list of rare diseases. Journal of Rare Diseases. 2024; 3:195-201. (in Chinese)"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Ali M, Wani SUD, Masoodi MH, Khan NA, Shivakumar HG, Osmani RMA, Khan KA. Global effect of COVID-19 pandemic on cancer patients and its treatment: A systematic review. Clin Complement Med Pharmacol. 2022; 2:100041.","DOI":"10.1016\/j.ccmp.2022.100041"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Xiao H, Dai X, Wagenaar BH, Liu F, Augusto O, Guo Y, Unger JM. The impact of the COVID-19 pandemic on health services utilization in China: Time-series analyses for 2016-2020. Lancet Reg Health West Pac. 2021; 9:100122.","DOI":"10.1016\/j.lanwpc.2021.100122"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Xu S, Glenn S, Sy L, Qian L, Hong V, Ryan DS, Jacobsen S. Impact of the COVID-19 pandemic on health care utilization in a large integrated health care system: Retrospective Cohort Study. J Med Internet Res. 2021; 23:e26558.","DOI":"10.2196\/26558"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Macaluso M, Rothenberg ME, Ferkol T, Kuhnell P, Kaminski HJ, Kimberlin DW, Benatar M, Chehade M; Principal investigators of the rare diseases clinical research network \u2013 cycle 4. Impact of the COVID-19 pandemic on people living with rare diseases and their families: Results of a national survey. JMIR Public Health Surveill. 2024; 10:e48430.","DOI":"10.2196\/48430"}],"container-title":["Intractable &amp; Rare Diseases Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/14\/4\/14_2025.01025\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:42:01Z","timestamp":1764996121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/14\/4\/14_2025.01025\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,30]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5582\/irdr.2025.01025","relation":{},"ISSN":["2186-361X","2186-3644"],"issn-type":[{"type":"electronic","value":"2186-361X"},{"type":"print","value":"2186-3644"}],"subject":[],"published":{"date-parts":[[2025,11,30]]},"article-number":"2025.01025"}}